883 related articles for article (PubMed ID: 28121498)
1. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.
Wilcox MH; Gerding DN; Poxton IR; Kelly C; Nathan R; Birch T; Cornely OA; Rahav G; Bouza E; Lee C; Jenkin G; Jensen W; Kim YS; Yoshida J; Gabryelski L; Pedley A; Eves K; Tipping R; Guris D; Kartsonis N; Dorr MB;
N Engl J Med; 2017 Jan; 376(4):305-317. PubMed ID: 28121498
[TBL] [Abstract][Full Text] [Related]
2. The effect of bezlotoxumab for prevention of recurrent Clostridium difficile infection (CDI) in Japanese patients.
Mikamo H; Aoyama N; Sawata M; Fujimoto G; Dorr MB; Yoshinari T
J Infect Chemother; 2018 Feb; 24(2):123-129. PubMed ID: 29097028
[TBL] [Abstract][Full Text] [Related]
3. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
Gerding DN; Kelly CP; Rahav G; Lee C; Dubberke ER; Kumar PN; Yacyshyn B; Kao D; Eves K; Ellison MC; Hanson ME; Guris D; Dorr MB
Clin Infect Dis; 2018 Aug; 67(5):649-656. PubMed ID: 29538686
[TBL] [Abstract][Full Text] [Related]
4. Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment?
Posteraro B; Pea F; Masucci L; Posteraro P; Sanguinetti M
Expert Opin Biol Ther; 2018 Apr; 18(4):469-476. PubMed ID: 29534621
[TBL] [Abstract][Full Text] [Related]
5. Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection.
Kufel WD; Devanathan AS; Marx AH; Weber DJ; Daniels LM
Pharmacotherapy; 2017 Oct; 37(10):1298-1308. PubMed ID: 28730660
[TBL] [Abstract][Full Text] [Related]
6. Analysis of C. difficile infection-related outcomes in European participants in the bezlotoxumab MODIFY I and II trials.
Bouza E; Cornely OA; Ramos-Martinez A; Plesniak R; Ellison MC; Hanson ME; Dorr MB
Eur J Clin Microbiol Infect Dis; 2020 Oct; 39(10):1933-1939. PubMed ID: 32504314
[TBL] [Abstract][Full Text] [Related]
7. Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?
Chapin RW; Lee T; McCoy C; Alonso CD; Mahoney MV
Ann Pharmacother; 2017 Sep; 51(9):804-810. PubMed ID: 28480750
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection.
Prabhu VS; Dubberke ER; Dorr MB; Elbasha E; Cossrow N; Jiang Y; Marcella S
Clin Infect Dis; 2018 Jan; 66(3):355-362. PubMed ID: 29106516
[TBL] [Abstract][Full Text] [Related]
9. Genetic Association Reveals Protection against Recurrence of
Shen J; Mehrotra DV; Dorr MB; Zeng Z; Li J; Xu X; Nickle D; Holzinger ER; Chhibber A; Wilcox MH; Blanchard RL; Shaw PM
mSphere; 2020 May; 5(3):. PubMed ID: 32376702
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of bezlotoxumab based on timing of administration relative to start of antibacterial therapy for Clostridium difficile infection.
Birch T; Golan Y; Rizzardini G; Jensen E; Gabryelski L; Guris D; Dorr MB
J Antimicrob Chemother; 2018 Sep; 73(9):2524-2528. PubMed ID: 29788418
[TBL] [Abstract][Full Text] [Related]
11. Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II.
Goldstein EJC; Citron DM; Gerding DN; Wilcox MH; Gabryelski L; Pedley A; Zeng Z; Dorr MB
Clin Infect Dis; 2020 Aug; 71(4):1102-1105. PubMed ID: 31883370
[TBL] [Abstract][Full Text] [Related]
12. Bezlotoxumab: A Review in Preventing Clostridium difficile Infection Recurrence.
Deeks ED
Drugs; 2017 Oct; 77(15):1657-1663. PubMed ID: 28865041
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Monoclonal Antibodies Against Clostridioides difficile Toxins for Prevention of Recurrent Clostridioides difficile Infection: A Systematic Review and Meta-Analysis.
Akiyama S; Yamada A; Komaki Y; Komaki F; Micic D; Sakuraba A
J Clin Gastroenterol; 2021 Jan; 55(1):43-51. PubMed ID: 32053529
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Bezlotoxumab in Trial Participants Infected With Clostridioides difficile Strain BI Associated With Poor Outcomes.
Johnson S; Citron DM; Gerding DN; Wilcox MH; Goldstein EJC; Sambol SP; Best EL; Eves K; Jensen E; Dorr MB
Clin Infect Dis; 2021 Nov; 73(9):e2616-e2624. PubMed ID: 32735653
[TBL] [Abstract][Full Text] [Related]
15. The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with
Džunková M; D'Auria G; Xu H; Huang J; Duan Y; Moya A; Kelly CP; Chen X
Front Cell Infect Microbiol; 2016; 6():119. PubMed ID: 27757389
[TBL] [Abstract][Full Text] [Related]
16. Bezlotoxumab for the treatment of Clostridium difficile-associated diarrhea.
Thakare R; Dasgupta A; Chopra S
Drugs Today (Barc); 2017 Jul; 53(7):385-392. PubMed ID: 28837182
[TBL] [Abstract][Full Text] [Related]
17. Broad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modeling.
Hernandez LD; Racine F; Xiao L; DiNunzio E; Hairston N; Sheth PR; Murgolo NJ; Therien AG
Antimicrob Agents Chemother; 2015 Feb; 59(2):1052-60. PubMed ID: 25451052
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain.
Salavert M; Cobo J; Pascual Á; Aragón B; Maratia S; Jiang Y; Aceituno S; Grau S
Adv Ther; 2018 Nov; 35(11):1920-1934. PubMed ID: 30328061
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent
Yee KL; Kleijn HJ; Kerbusch T; Matthews RP; Dorr MB; Garey KW; Wrishko RE
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455246
[TBL] [Abstract][Full Text] [Related]
20. Bezlotoxumab for the Prevention of
Chahine EB; Cho JC; Worley MV
Consult Pharm; 2018 Feb; 33(2):89-97. PubMed ID: 29409575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
